Research Study

An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA Nephropathy
Principal Investigator 
Sean Barbour

Overview

Body Locations and Systems 
Kidney Disease
ClinicalTrials.gov# 
NCT04014335
Status 
Recruiting
Study Start/End 
Jan 24, 2020 to Jan 31, 2021
Locations 
Diamond Health Care Centre
Name/Title 
Katy Vela, Study Coordinator
Phone 
604-806-9460
Purpose of Study 

 

The purpose of this study is to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B messenger ribonucleic acid (CFB mRNA), and to evaluate the effect of IONIS-FB-LRx on plasma factor B (FB) levels and serum AH50, CH50 activity in participants with primary immunoglobulin A (IgA) nephropathy.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.